tiprankstipranks
Recce Pharmaceuticals Ltd. (AU:RCE)
ASX:RCE

Recce Pharmaceuticals Ltd. (RCE) Income Statement

4 Followers

Recce Pharmaceuticals Ltd. Income Statement

Last quarter (Q4 2022), Recce Pharmaceuticals Ltd.'s total revenue was AU$―, a decrease of ― from the same quarter last year. In Q4, Recce Pharmaceuticals Ltd.'s net income was AU$―. See Recce Pharmaceuticals Ltd.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Jun 22Jun 21Jun 20Jun 19Jun 18
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
-AU$ 12.60MAU$ 15.20MAU$ 5.26MAU$ 3.31MAU$ 2.82M
Operating Income
-AU$ -12.60MAU$ -15.20MAU$ -5.26MAU$ -3.31MAU$ -2.82M
Net Non Operating Interest Income Expense
-AU$ 79.07KAU$ 93.62KAU$ -30.64KAU$ -49.70KAU$ -42.29K
Other Income Expense
-AU$ 1.53MAU$ 1.59MAU$ 974.23KAU$ 571.34KAU$ 1.19M
Pretax Income
-AU$ -10.99MAU$ -13.51MAU$ -4.32MAU$ -2.79MAU$ -1.67M
Tax Provision
-AU$ 0.00AU$ 0.00AU$ 0.00AU$ 0.00AU$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-AU$ -10.99MAU$ -13.51MAU$ -4.32MAU$ -2.79MAU$ -1.67M
Basic EPS
-AU$ -0.06AU$ -0.09AU$ -0.03AU$ -0.03-
Diluted EPS
-AU$ -0.06AU$ -0.09AU$ -0.03AU$ -0.03-
Basic Average Shares
-AU$ 174.13MAU$ 155.40MAU$ 127.21MAU$ 94.47M-
Diluted Average Shares
-AU$ 174.13MAU$ 155.40MAU$ 127.21MAU$ 94.47M-
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
------
Net Income From Continuing And Discontinued Operation
-AU$ -10.99MAU$ -13.51MAU$ -4.32MAU$ -2.79MAU$ -1.67M
Normalized Income
-AU$ -10.99MAU$ -13.51MAU$ -4.32MAU$ -2.79MAU$ -1.67M
Interest Expense
-AU$ 2.42KAU$ 2.11KAU$ 45.85KAU$ 56.69KAU$ 54.31K
EBIT
-AU$ -10.98MAU$ -13.51MAU$ -4.27MAU$ -2.73MAU$ -1.62M
EBITDA
-AU$ -10.80MAU$ -13.22MAU$ -4.07MAU$ -2.68MAU$ -1.57M
Currency in AUD

Recce Pharmaceuticals Ltd. Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis